La NMPA de China aprueba la comercialización de Ganagliflozin Proline Tablets
📩 info@dengyuemed.com
🔗https://dengyuepharma.com
#NMPA #ChinaDrugApproval #GanagliflozinProline #SGLT2Inhibitor #Type2Diabetes #InnovativeDrug #PharmaceuticalNews
China NMPA Grants Conditional Approval for Garsorasib Tablets
📩 info@dengyuemed.com
🔗https://dengyuemed.com
#ChinaNMPA #DrugApproval #Garsorasib #NSCLC #KRASG12C #InnovativeDrug #ChiataiTianqing #LungCancer
China NMPA Approves Pradefovir Mesylate Tablets for Marketing
📩 info@dengyuemed.com
🔗https://dengyuemed.com
#NMPA #ChinaDrugApproval #PradefovirMesylate #Xinshumu #HepatitisB #InnovativeDrug #XiAnGelanXintong #PharmaceuticalNews
China NMPA Approves Funakizumab Injection for Moderate-to-Severe Plaque Psoriasis
📩 info@dengyuemed.com
🔗https://dengyuemed.com
#NMPA #DrugApproval #MonoclonalAntibody #IL17A #Psoriasis #BiopharmaChina #InnovativeDrug
National Medical Products Administration (NMPA) has approved the marketing of Cogriptin Tablets.
📩 info@dengyuemed.com
🔗 dengyuemed.com
#Cogriptin #Beichangping #HisunPharma #Type2Diabetes #DPP4Inhibitor #GLP1 #GIP #NMPA #ChinaPharma #InnovativeDrug #DiabetesTreatment #BloodGlucoseControl
The Innovation Conference 2025 - Topic 14: The Current Status and Future of Innovative Drug R&D.
This session will feature discussions on current challenges in China's innovative drug #research and key R&D directions for next-generation drugs.
conference.the-innovation.org/xinn/
#Innovativedrug
